No results for ‘’
Sandu Pharmaceuticals Ltd
₹37.01
(2.30%)
Tue, 15 Sept 2026, 03:44 am
Health Technology
Pharmaceuticals: Other
24.5KSandu Pharmaceuticals Ratios
| Particulars | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 6.31 | 13.68 | 10.79 | 21.54 | 10.91 | 14.17 | 37.93 | 32.43 | 52.92 | 36.27 | 23.07 | 11.55 | 20.73 | 37.64 | 32.38 | 37.94 | 30.50 |
| Price to book ratio | 0.37 | 0.61 | 0.54 | 0.61 | 0.49 | 0.39 | 0.86 | 0.93 | 0.82 | 0.72 | 0.54 | 0.28 | 0.76 | 1.70 | 1.29 | 1.37 | 1.13 |
| Price to sales ratio | 0.38 | 0.61 | 0.41 | 0.38 | 0.29 | 0.20 | 0.41 | 0.45 | 0.52 | 0.41 | 0.31 | 0.17 | 0.39 | 0.91 | 0.75 | 0.82 | 0.70 |
| Price to cash flow ratio | 48.12 | 8.83 | 9.49 | 0 | 2.45 | 0 | 4.45 | 0 | 6.54 | 728.44 | 5.64 | 1.44 | 2.95 | 64.95 | 164.40 | 64.76 | 49.53 |
| Enterprise value | 8.13Cr | 11.1Cr | 10.08Cr | 13.49Cr | 13.36Cr | 15.5Cr | 23.87Cr | 28.15Cr | 30.35Cr | 28.3Cr | 20.82Cr | 8.02Cr | 11.01Cr | 55.65Cr | 46.94Cr | 54.3Cr | 45.15Cr |
| Enterprise value to EBITDA ratio | 5.09 | 7.12 | 6.03 | 7.30 | 6.88 | 7.24 | 10.59 | 9.80 | 16.27 | 11.42 | 9.78 | 5.50 | 5.12 | 19.35 | 18.88 | 23.65 | 16.33 |
| Debt to equity ratio | 0.19 | 0.19 | 0.17 | 0.24 | 0.48 | 0.55 | 0.69 | 0.61 | 0.39 | 0.34 | 0.21 | 0.04 | 0 | 0 | 0 | 0 | 0.01 |
| Return on equity % | 0 | 4.55 | 5.13 | 2.92 | 4.53 | 2.78 | 2.28 | 2.92 | -1.93 | 2.38 | 2.35 | 2.48 | 3.48 | 4.54 | 4.02 | 3.66 | 3.76 |
Sandu Pharmaceuticals Ltd Ratios
The Sandu Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Sandu Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Sandu Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Sandu Pharmaceuticals Ltd (NSE: , BSE: 524703) is currently trading at ₹37.01, with a market capitalization of ₹35.76Cr. As a major player in the Health technology sector and Pharmaceuticals: other industry, Sandu Pharmaceuticals Ltd remains a key stock for fundamental analysis using Sandu Pharmaceuticals Ltd Ratios.
Sandu Pharmaceuticals Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Sandu Pharmaceuticals Ltd P/E ratio currently stands at 30.50, making it one of the most tracked metrics in Sandu Pharmaceuticals Ltd Ratios.
Historically, the Sandu Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:
- 2024: 30.50
- 2023: 37.94
- 2022: 32.38
- 2021: 37.64
- 2020: 20.73
The decline in Sandu Pharmaceuticals Ltd P/E ratio suggests improving earnings relative to stock price.
Price to Book Ratio (P/B)
The Sandu Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.13.
Historical P/B trend:
- 2024: 1.13
- 2023: 1.37
- 2022: 1.29
- 2021: 1.70
Sandu Pharmaceuticals Ltd shows reasonable valuation compared to its asset base.
Price to Sales Ratio (P/S)
The Sandu Pharmaceuticals Ltd P/S ratio currently stands at 0.70, an important part of Sandu Pharmaceuticals Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 0.70
- 2023: 0.82
- 2022: 0.75
- 2021: 0.91
A stable or declining Sandu Pharmaceuticals Ltd P/S ratio indicates cautious market sentiment.
Sandu Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)
The Sandu Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 49.53.
Historical Sandu Pharmaceuticals Ltd Price to Cash Flow Ratio:
- 2024: 49.53
- 2023: 64.76
- 2022: 164.40
- 2021: 64.95
- 2020: 2.95
The declining Sandu Pharmaceuticals Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
Sandu Pharmaceuticals Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Sandu Pharmaceuticals Ltd EV currently stands at ₹45.15Cr, representing the total company valuation including debt.
Historical EV trend:
- 2024: 45.15Cr
- 2023: 54.3Cr
- 2022: 46.94Cr
- 2021: 55.65Cr
Sandu Pharmaceuticals Ltd enterprise value consolidation suggests stable valuation.
EV/EBITDA Ratio
The Sandu Pharmaceuticals Ltd EV/EBITDA ratio is currently 16.33, a key metric in Sandu Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 16.33
- 2023: 23.65
- 2022: 18.88
- 2021: 19.35
Stable Sandu Pharmaceuticals Ltd EV/EBITDA indicates balanced valuation.
Sandu Pharmaceuticals Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Sandu Pharmaceuticals Ltd D/E ratio is currently 0.01, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.01
- 2023: 0
- 2022: 0
- 2021: 0
Sandu Pharmaceuticals Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Sandu Pharmaceuticals Ltd ROE currently stands at 3.76%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 3.76
- 2023: 3.66
- 2022: 4.02
- 2021: 4.54
Declining ROE indicates pressure on profitability.
Sandu Pharmaceuticals Ltd Ratios Analysis Summary
The Sandu Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Sandu Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Sandu Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.